Insmed's CEO William Lewis Buys Shares of INSM

William Lewis, the Chair and CEO of Insmed Incorporated, made a notable purchase of 21,398 shares on June 25, 2026. The shares were bought at an average price of $24.94 each, totaling approximately $533,678. This transaction was not part of a pre-arranged trading plan.

Insider Buying and Selling at Insmed Incorporated

On June 25, 2026, William Lewis, Chair and CEO of Insmed, acquired 21,398 shares at an average price of $24.94, amounting to $533,678. This purchase was not under a Rule 10b5-1 plan. In the same period, Samuele Butera, SVP and GM of Global Respiratory, also bought shares, while Michael Alexander Smith, Chief Legal Officer, sold shares under a planned transaction.

Other Institutional Activity in Insmed Incorporated

JPMorgan Chase & Co increased its holdings in Insmed by 950,987 shares, bringing its total to 24,150,499 shares valued at about $3.7 billion, marking a 4.1% increase. Darwin Global Management, Ltd. reduced its stake by 4,128,093 shares, ending with 16,805,184 shares worth approximately $2.58 billion, a 19.7% decrease. BlackRock, Inc. added 1,613,094 shares, now holding 16,678,146 shares valued at $2.73 billion, a 10.7% increase. FMR LLC boosted its position by 3,232,231 shares to 13,160,167 shares, valued at $2.15 billion, a 32.6% increase. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both opened new positions with 10,371,802 shares and 9,642,131 shares, respectively.

Insmed Incorporated Stock Down 12.8%

Shares of NasdaqGS:INSM traded near $104.47 on Saturday. Insmed has a market capitalization of $22.4 billion and a forward P/E ratio of 748.1. The stock's beta is 0.774, indicating lower volatility compared to the market. It has a 52-week low of $90.39 and a high of $212.75, with a 50-day moving average of $114.32 and a 200-day moving average of $152.52. The company's current ratio is 4.47, with a quick ratio of 3.88 and a debt-to-equity ratio of 105.34.

Analysts Set New Price Targets

On June 22, 2026, Evercore ISI Group maintained its buy rating for Insmed with a price target of $160. JP Morgan also maintained a buy rating with a target of $179 on June 8. RBC Capital reiterated its buy rating with a $195 target on June 5. Overall, analysts hold a strong buy consensus for Insmed, with a mean price target of $197.05 based on 21 analyst opinions.

About Insmed Incorporated

Insmed Incorporated is a biotechnology company based in Bridgewater, New Jersey. It focuses on developing and commercializing therapies for serious and rare diseases. The company offers ARIKAYCE for treating lung infections and is working on several other treatments in various stages of clinical trials, including therapies for bronchiectasis, pulmonary hypertension, and Duchenne muscular dystrophy. Insmed is led by CEO William H. Lewis and employs approximately 1,664 people.

Bottom Line

William Lewis's recent share purchase highlights insider confidence in Insmed's prospects. The company's stock is trading near its 52-week low, providing a potential opportunity for investors tracking insider activities. With a strong buy consensus from analysts, Insmed remains a company to watch in the biotechnology sector.